ASMB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States...

Stats
Today's Volume	5 463.00
Average Volume	17 442.00
Market Cap	83.53M
EPS	$0 ( 2024-05-29 )
Next earnings date	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.168 (1.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-29	Johnson-pratt Lisa	Buy	2 750	Stock Option (right to buy)
2024-05-29	Mchutchison John G	Buy	2 750	Stock Option (right to buy)
2024-05-29	Mahony Susan	Buy	2 750	Stock Option (right to buy)
2024-05-29	Houghton Michael	Buy	2 750	Stock Option (right to buy)
2024-05-29	Consylman Gina	Buy	2 750	Stock Option (right to buy)

INSIDER POWER
65.15
Last 96 transactions
Buy: 3 559 812 \| Sell: 641 819

Assembly Biosciences Inc Correlation

10 Most Positive Correlations
OZEM	1
CCSB	0.91
BUFF	0.908
KBWP	0.905
CRDL	0.904
TARS	0.899
DVOL	0.897
CBHAX	0.895
DUSA	0.894
FNILX	0.893

10 Most Negative Correlations
GP	-0.913
AMPL	-0.911
ENGN	-0.897
AAME	-0.894
JTAI	-0.894
CARM	-0.884
TROO	-0.883
LGVN	-0.881
ARBB	-0.879
LUXH	-0.878

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Assembly Biosciences Inc Financials

Annual	2023
Revenue:	$7.16M
Gross Profit:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2023
Revenue:	$7.16M
Gross Profit:	$6.71M (93.72 %)
EPS:	$-13.38

FY	2022
Revenue:	$0
Gross Profit:	$-498 000 (0.00 %)
EPS:	$-22.82

FY	2021
Revenue:	$6.25M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-3.67

Financial Reports:

No articles found.

Assembly Biosciences Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Assembly Biosciences Inc

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.